Global Cancer Pain Therapeutics Market

Cancer Pain Therapeutics Comprehensive Study by Type (Opioids, Non-Steroidal Anti-Inflammatory Drugs, Others), Application (Related Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy), End User (Hospitals, Healthcare Research Institutes) Players and Region - Global Market Outlook to 2029

Cancer Pain Therapeutics Market by XX Submarkets | Forecast Years 2024-2029 | CAGR: 9.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cancer Pain Therapeutics
Cancer Pain Therapeutics is drugs that are available for dropping pain associated with cancer have a lengthy period of action. Cancer pain can be acute or chronic. It is reliant on its stages and types. There are various type of drug available for reducing pain such as Opioids, Non-Steroidal Anti-Inflammatory Drugs and Others, which is helpful for immunotherapy, radiotherapy, and chemotherapy and hormone therapy. Pain control is imperative not only for people who have advanced cancer but also for those whose disorder remains stable for years.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
CAGR9.4%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Cancer Pain Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

BioDelivery Science (United States), ProStrakan Group (United Kingdom), Teva Pharmaceuticals (Israel), Daiichi Sankyo (Japan), Eli-lilly (United States), Galena Biopharma (United States), Grunenthal Group (Germany), GW Pharmaceuticals (United Kingdom), Hospira (United States) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Meda Pharmaceuticals (United Kingdom), Orexo (Sweden), Sanofi (France) and Sorrento Therapeutics (United States).

Segmentation Overview
AMA Research has segmented the market of Global Cancer Pain Therapeutics market by Type (Opioids, Non-Steroidal Anti-Inflammatory Drugs and Others), Application (Related Immunotherapy, Radiotherapy, Chemotherapy and Hormone Therapy) and Region.



On the basis of geography, the market of Cancer Pain Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, Sweden, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Israel, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Cancer Pain Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase Awareness about Cancer Pain Therapy and Rising Demand of Non-steroidal anti-inflammatory drugs

Market Growth Drivers:
Unmet Medical Requirements and Rising Medical and Healthcare Expenditure

Restraints:
High Price For Therapy

Opportunities:
Technological Advancement in the Pain Therapy Related Devices and Off-label Drug Use

Market Leaders and their expansionary development strategies
In June 2018, Eli Lilly and Company has acquired ARMO BioSciences, Inc. at a price of 50 dollar per share in cash.
In May 2018, Daiichi Sankyo Company has launched injection for cancer therapeutics in japan named as NaruveinⓇ Injection 2 mg • 20 mg (generic name: hydromorphone hydrochloride).


Key Target Audience
Cancer Pain Therapeutics Service Provider, Pharmaceuticals Industry, Healthcare Industry, Industry Associations and Experts, Private Research Organizations and Consulting Companies, Industry Associations, Government Market Research and Consulting Firm and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Opioids
  • Non-Steroidal Anti-Inflammatory Drugs
  • Others
By Application
  • Related Immunotherapy
  • Radiotherapy
  • Chemotherapy
  • Hormone Therapy
By End User
  • Hospitals
  • Healthcare Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • Sweden
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Israel
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Unmet Medical Requirements
      • 3.2.2. Rising Medical and Healthcare Expenditure
    • 3.3. Market Trends
      • 3.3.1. Increase Awareness about Cancer Pain Therapy
      • 3.3.2. Rising Demand of Non-steroidal anti-inflammatory drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Pain Therapeutics, by Type, Application, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Cancer Pain Therapeutics (Value)
      • 5.2.1. Global Cancer Pain Therapeutics by: Type (Value)
        • 5.2.1.1. Opioids
        • 5.2.1.2. Non-Steroidal Anti-Inflammatory Drugs
        • 5.2.1.3. Others
      • 5.2.2. Global Cancer Pain Therapeutics by: Application (Value)
        • 5.2.2.1. Related Immunotherapy
        • 5.2.2.2. Radiotherapy
        • 5.2.2.3. Chemotherapy
        • 5.2.2.4. Hormone Therapy
      • 5.2.3. Global Cancer Pain Therapeutics by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Healthcare Research Institutes
      • 5.2.4. Global Cancer Pain Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. Sweden
          • 5.2.4.3.5. United Kingdom
          • 5.2.4.3.6. Netherlands
          • 5.2.4.3.7. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Israel
          • 5.2.4.4.3. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cancer Pain Therapeutics (Volume)
      • 5.3.1. Global Cancer Pain Therapeutics by: Type (Volume)
        • 5.3.1.1. Opioids
        • 5.3.1.2. Non-Steroidal Anti-Inflammatory Drugs
        • 5.3.1.3. Others
      • 5.3.2. Global Cancer Pain Therapeutics by: Application (Volume)
        • 5.3.2.1. Related Immunotherapy
        • 5.3.2.2. Radiotherapy
        • 5.3.2.3. Chemotherapy
        • 5.3.2.4. Hormone Therapy
      • 5.3.3. Global Cancer Pain Therapeutics by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Healthcare Research Institutes
      • 5.3.4. Global Cancer Pain Therapeutics Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. Sweden
          • 5.3.4.3.5. United Kingdom
          • 5.3.4.3.6. Netherlands
          • 5.3.4.3.7. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Israel
          • 5.3.4.4.3. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Cancer Pain Therapeutics (Price)
      • 5.4.1. Global Cancer Pain Therapeutics by: Type (Price)
  • 6. Cancer Pain Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioDelivery Science (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ProStrakan Group (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceuticals (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Daiichi Sankyo (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli-lilly (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galena Biopharma (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Grunenthal Group (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GW Pharmaceuticals (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hospira (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Pain Therapeutics Sale, by Type, Application, End User and Region (value, volume and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Cancer Pain Therapeutics (Value)
      • 7.2.1. Global Cancer Pain Therapeutics by: Type (Value)
        • 7.2.1.1. Opioids
        • 7.2.1.2. Non-Steroidal Anti-Inflammatory Drugs
        • 7.2.1.3. Others
      • 7.2.2. Global Cancer Pain Therapeutics by: Application (Value)
        • 7.2.2.1. Related Immunotherapy
        • 7.2.2.2. Radiotherapy
        • 7.2.2.3. Chemotherapy
        • 7.2.2.4. Hormone Therapy
      • 7.2.3. Global Cancer Pain Therapeutics by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Healthcare Research Institutes
      • 7.2.4. Global Cancer Pain Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. Sweden
          • 7.2.4.3.5. United Kingdom
          • 7.2.4.3.6. Netherlands
          • 7.2.4.3.7. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Israel
          • 7.2.4.4.3. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cancer Pain Therapeutics (Volume)
      • 7.3.1. Global Cancer Pain Therapeutics by: Type (Volume)
        • 7.3.1.1. Opioids
        • 7.3.1.2. Non-Steroidal Anti-Inflammatory Drugs
        • 7.3.1.3. Others
      • 7.3.2. Global Cancer Pain Therapeutics by: Application (Volume)
        • 7.3.2.1. Related Immunotherapy
        • 7.3.2.2. Radiotherapy
        • 7.3.2.3. Chemotherapy
        • 7.3.2.4. Hormone Therapy
      • 7.3.3. Global Cancer Pain Therapeutics by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Healthcare Research Institutes
      • 7.3.4. Global Cancer Pain Therapeutics Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. Sweden
          • 7.3.4.3.5. United Kingdom
          • 7.3.4.3.6. Netherlands
          • 7.3.4.3.7. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Israel
          • 7.3.4.4.3. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Cancer Pain Therapeutics (Price)
      • 7.4.1. Global Cancer Pain Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Pain Therapeutics: by Type(USD Million)
  • Table 2. Cancer Pain Therapeutics Opioids , by Region USD Million (2018-2023)
  • Table 3. Cancer Pain Therapeutics Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2018-2023)
  • Table 4. Cancer Pain Therapeutics Others , by Region USD Million (2018-2023)
  • Table 5. Cancer Pain Therapeutics: by Application(USD Million)
  • Table 6. Cancer Pain Therapeutics Related Immunotherapy , by Region USD Million (2018-2023)
  • Table 7. Cancer Pain Therapeutics Radiotherapy , by Region USD Million (2018-2023)
  • Table 8. Cancer Pain Therapeutics Chemotherapy , by Region USD Million (2018-2023)
  • Table 9. Cancer Pain Therapeutics Hormone Therapy , by Region USD Million (2018-2023)
  • Table 10. Cancer Pain Therapeutics: by End User(USD Million)
  • Table 11. Cancer Pain Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 12. Cancer Pain Therapeutics Healthcare Research Institutes , by Region USD Million (2018-2023)
  • Table 13. South America Cancer Pain Therapeutics, by Country USD Million (2018-2023)
  • Table 14. South America Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 15. South America Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 16. South America Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 17. Brazil Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 18. Brazil Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 19. Brazil Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 20. Argentina Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 21. Argentina Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 22. Argentina Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 23. Rest of South America Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 24. Rest of South America Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 26. Asia Pacific Cancer Pain Therapeutics, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 28. Asia Pacific Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 30. China Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 31. China Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 32. China Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 33. Japan Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 34. Japan Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 35. Japan Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 36. India Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 37. India Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 38. India Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 39. South Korea Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 40. South Korea Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 41. South Korea Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 42. Taiwan Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 43. Taiwan Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 44. Taiwan Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 45. Australia Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 46. Australia Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 47. Australia Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 51. Europe Cancer Pain Therapeutics, by Country USD Million (2018-2023)
  • Table 52. Europe Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 53. Europe Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 54. Europe Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 55. Germany Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 56. Germany Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 57. Germany Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 58. France Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 59. France Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 60. France Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 61. Italy Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 62. Italy Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 63. Italy Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 64. Sweden Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 65. Sweden Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 66. Sweden Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 67. United Kingdom Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 70. Netherlands Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 71. Netherlands Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 72. Netherlands Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 73. Rest of Europe Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 76. MEA Cancer Pain Therapeutics, by Country USD Million (2018-2023)
  • Table 77. MEA Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 78. MEA Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 79. MEA Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 80. Middle East Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 81. Middle East Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 82. Middle East Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 83. Israel Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 84. Israel Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 85. Israel Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 86. Africa Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 87. Africa Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 88. Africa Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 89. North America Cancer Pain Therapeutics, by Country USD Million (2018-2023)
  • Table 90. North America Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 91. North America Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 92. North America Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 93. United States Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 94. United States Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 95. United States Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 96. Canada Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 97. Canada Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 98. Canada Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 99. Mexico Cancer Pain Therapeutics, by Type USD Million (2018-2023)
  • Table 100. Mexico Cancer Pain Therapeutics, by Application USD Million (2018-2023)
  • Table 101. Mexico Cancer Pain Therapeutics, by End User USD Million (2018-2023)
  • Table 102. Cancer Pain Therapeutics Sales: by Type(K Tons)
  • Table 103. Cancer Pain Therapeutics Sales Opioids , by Region K Tons (2018-2023)
  • Table 104. Cancer Pain Therapeutics Sales Non-Steroidal Anti-Inflammatory Drugs , by Region K Tons (2018-2023)
  • Table 105. Cancer Pain Therapeutics Sales Others , by Region K Tons (2018-2023)
  • Table 106. Cancer Pain Therapeutics Sales: by Application(K Tons)
  • Table 107. Cancer Pain Therapeutics Sales Related Immunotherapy , by Region K Tons (2018-2023)
  • Table 108. Cancer Pain Therapeutics Sales Radiotherapy , by Region K Tons (2018-2023)
  • Table 109. Cancer Pain Therapeutics Sales Chemotherapy , by Region K Tons (2018-2023)
  • Table 110. Cancer Pain Therapeutics Sales Hormone Therapy , by Region K Tons (2018-2023)
  • Table 111. Cancer Pain Therapeutics Sales: by End User(K Tons)
  • Table 112. Cancer Pain Therapeutics Sales Hospitals , by Region K Tons (2018-2023)
  • Table 113. Cancer Pain Therapeutics Sales Healthcare Research Institutes , by Region K Tons (2018-2023)
  • Table 114. South America Cancer Pain Therapeutics Sales, by Country K Tons (2018-2023)
  • Table 115. South America Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 116. South America Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 117. South America Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 118. Brazil Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 119. Brazil Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 120. Brazil Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 121. Argentina Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 122. Argentina Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 123. Argentina Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 124. Rest of South America Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 125. Rest of South America Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 126. Rest of South America Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 127. Asia Pacific Cancer Pain Therapeutics Sales, by Country K Tons (2018-2023)
  • Table 128. Asia Pacific Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 129. Asia Pacific Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 130. Asia Pacific Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 131. China Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 132. China Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 133. China Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 134. Japan Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 135. Japan Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 136. Japan Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 137. India Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 138. India Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 139. India Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 140. South Korea Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 141. South Korea Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 142. South Korea Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 143. Taiwan Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 144. Taiwan Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 145. Taiwan Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 146. Australia Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 147. Australia Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 148. Australia Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 149. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 150. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 151. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 152. Europe Cancer Pain Therapeutics Sales, by Country K Tons (2018-2023)
  • Table 153. Europe Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 154. Europe Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 155. Europe Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 156. Germany Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 157. Germany Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 158. Germany Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 159. France Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 160. France Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 161. France Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 162. Italy Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 163. Italy Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 164. Italy Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 165. Sweden Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 166. Sweden Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 167. Sweden Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 168. United Kingdom Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 169. United Kingdom Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 170. United Kingdom Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 171. Netherlands Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 172. Netherlands Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 173. Netherlands Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 174. Rest of Europe Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 175. Rest of Europe Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 176. Rest of Europe Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 177. MEA Cancer Pain Therapeutics Sales, by Country K Tons (2018-2023)
  • Table 178. MEA Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 179. MEA Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 180. MEA Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 181. Middle East Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 182. Middle East Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 183. Middle East Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 184. Israel Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 185. Israel Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 186. Israel Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 187. Africa Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 188. Africa Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 189. Africa Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 190. North America Cancer Pain Therapeutics Sales, by Country K Tons (2018-2023)
  • Table 191. North America Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 192. North America Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 193. North America Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 194. United States Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 195. United States Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 196. United States Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 197. Canada Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 198. Canada Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 199. Canada Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 200. Mexico Cancer Pain Therapeutics Sales, by Type K Tons (2018-2023)
  • Table 201. Mexico Cancer Pain Therapeutics Sales, by Application K Tons (2018-2023)
  • Table 202. Mexico Cancer Pain Therapeutics Sales, by End User K Tons (2018-2023)
  • Table 203. Cancer Pain Therapeutics: by Type(USD/Units)
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Cancer Pain Therapeutics: by Type(USD Million)
  • Table 215. Cancer Pain Therapeutics Opioids , by Region USD Million (2024-2029)
  • Table 216. Cancer Pain Therapeutics Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2024-2029)
  • Table 217. Cancer Pain Therapeutics Others , by Region USD Million (2024-2029)
  • Table 218. Cancer Pain Therapeutics: by Application(USD Million)
  • Table 219. Cancer Pain Therapeutics Related Immunotherapy , by Region USD Million (2024-2029)
  • Table 220. Cancer Pain Therapeutics Radiotherapy , by Region USD Million (2024-2029)
  • Table 221. Cancer Pain Therapeutics Chemotherapy , by Region USD Million (2024-2029)
  • Table 222. Cancer Pain Therapeutics Hormone Therapy , by Region USD Million (2024-2029)
  • Table 223. Cancer Pain Therapeutics: by End User(USD Million)
  • Table 224. Cancer Pain Therapeutics Hospitals , by Region USD Million (2024-2029)
  • Table 225. Cancer Pain Therapeutics Healthcare Research Institutes , by Region USD Million (2024-2029)
  • Table 226. South America Cancer Pain Therapeutics, by Country USD Million (2024-2029)
  • Table 227. South America Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 228. South America Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 229. South America Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 230. Brazil Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 231. Brazil Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 232. Brazil Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 233. Argentina Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 234. Argentina Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 235. Argentina Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 236. Rest of South America Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 237. Rest of South America Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 238. Rest of South America Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 239. Asia Pacific Cancer Pain Therapeutics, by Country USD Million (2024-2029)
  • Table 240. Asia Pacific Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 241. Asia Pacific Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 242. Asia Pacific Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 243. China Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 244. China Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 245. China Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 246. Japan Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 247. Japan Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 248. Japan Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 249. India Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 250. India Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 251. India Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 252. South Korea Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 253. South Korea Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 254. South Korea Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 255. Taiwan Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 256. Taiwan Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 257. Taiwan Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 258. Australia Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 259. Australia Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 260. Australia Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 261. Rest of Asia-Pacific Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 262. Rest of Asia-Pacific Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 263. Rest of Asia-Pacific Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 264. Europe Cancer Pain Therapeutics, by Country USD Million (2024-2029)
  • Table 265. Europe Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 266. Europe Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 267. Europe Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 268. Germany Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 269. Germany Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 270. Germany Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 271. France Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 272. France Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 273. France Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 274. Italy Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 275. Italy Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 276. Italy Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 277. Sweden Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 278. Sweden Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 279. Sweden Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 280. United Kingdom Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 281. United Kingdom Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 282. United Kingdom Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 283. Netherlands Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 284. Netherlands Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 285. Netherlands Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 286. Rest of Europe Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 287. Rest of Europe Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 288. Rest of Europe Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 289. MEA Cancer Pain Therapeutics, by Country USD Million (2024-2029)
  • Table 290. MEA Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 291. MEA Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 292. MEA Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 293. Middle East Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 294. Middle East Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 295. Middle East Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 296. Israel Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 297. Israel Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 298. Israel Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 299. Africa Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 300. Africa Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 301. Africa Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 302. North America Cancer Pain Therapeutics, by Country USD Million (2024-2029)
  • Table 303. North America Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 304. North America Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 305. North America Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 306. United States Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 307. United States Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 308. United States Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 309. Canada Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 310. Canada Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 311. Canada Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 312. Mexico Cancer Pain Therapeutics, by Type USD Million (2024-2029)
  • Table 313. Mexico Cancer Pain Therapeutics, by Application USD Million (2024-2029)
  • Table 314. Mexico Cancer Pain Therapeutics, by End User USD Million (2024-2029)
  • Table 315. Cancer Pain Therapeutics Sales: by Type(K Tons)
  • Table 316. Cancer Pain Therapeutics Sales Opioids , by Region K Tons (2024-2029)
  • Table 317. Cancer Pain Therapeutics Sales Non-Steroidal Anti-Inflammatory Drugs , by Region K Tons (2024-2029)
  • Table 318. Cancer Pain Therapeutics Sales Others , by Region K Tons (2024-2029)
  • Table 319. Cancer Pain Therapeutics Sales: by Application(K Tons)
  • Table 320. Cancer Pain Therapeutics Sales Related Immunotherapy , by Region K Tons (2024-2029)
  • Table 321. Cancer Pain Therapeutics Sales Radiotherapy , by Region K Tons (2024-2029)
  • Table 322. Cancer Pain Therapeutics Sales Chemotherapy , by Region K Tons (2024-2029)
  • Table 323. Cancer Pain Therapeutics Sales Hormone Therapy , by Region K Tons (2024-2029)
  • Table 324. Cancer Pain Therapeutics Sales: by End User(K Tons)
  • Table 325. Cancer Pain Therapeutics Sales Hospitals , by Region K Tons (2024-2029)
  • Table 326. Cancer Pain Therapeutics Sales Healthcare Research Institutes , by Region K Tons (2024-2029)
  • Table 327. South America Cancer Pain Therapeutics Sales, by Country K Tons (2024-2029)
  • Table 328. South America Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 329. South America Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 330. South America Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 331. Brazil Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 332. Brazil Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 333. Brazil Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 334. Argentina Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 335. Argentina Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 336. Argentina Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 337. Rest of South America Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 338. Rest of South America Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 339. Rest of South America Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 340. Asia Pacific Cancer Pain Therapeutics Sales, by Country K Tons (2024-2029)
  • Table 341. Asia Pacific Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 342. Asia Pacific Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 343. Asia Pacific Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 344. China Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 345. China Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 346. China Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 347. Japan Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 348. Japan Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 349. Japan Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 350. India Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 351. India Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 352. India Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 353. South Korea Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 354. South Korea Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 355. South Korea Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 356. Taiwan Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 357. Taiwan Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 358. Taiwan Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 359. Australia Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 360. Australia Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 361. Australia Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 362. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 363. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 364. Rest of Asia-Pacific Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 365. Europe Cancer Pain Therapeutics Sales, by Country K Tons (2024-2029)
  • Table 366. Europe Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 367. Europe Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 368. Europe Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 369. Germany Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 370. Germany Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 371. Germany Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 372. France Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 373. France Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 374. France Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 375. Italy Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 376. Italy Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 377. Italy Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 378. Sweden Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 379. Sweden Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 380. Sweden Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 381. United Kingdom Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 382. United Kingdom Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 383. United Kingdom Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 384. Netherlands Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 385. Netherlands Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 386. Netherlands Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 387. Rest of Europe Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 388. Rest of Europe Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 389. Rest of Europe Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 390. MEA Cancer Pain Therapeutics Sales, by Country K Tons (2024-2029)
  • Table 391. MEA Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 392. MEA Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 393. MEA Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 394. Middle East Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 395. Middle East Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 396. Middle East Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 397. Israel Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 398. Israel Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 399. Israel Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 400. Africa Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 401. Africa Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 402. Africa Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 403. North America Cancer Pain Therapeutics Sales, by Country K Tons (2024-2029)
  • Table 404. North America Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 405. North America Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 406. North America Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 407. United States Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 408. United States Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 409. United States Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 410. Canada Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 411. Canada Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 412. Canada Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 413. Mexico Cancer Pain Therapeutics Sales, by Type K Tons (2024-2029)
  • Table 414. Mexico Cancer Pain Therapeutics Sales, by Application K Tons (2024-2029)
  • Table 415. Mexico Cancer Pain Therapeutics Sales, by End User K Tons (2024-2029)
  • Table 416. Cancer Pain Therapeutics: by Type(USD/Units)
  • Table 417. Research Programs/Design for This Report
  • Table 418. Key Data Information from Secondary Sources
  • Table 419. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Pain Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Cancer Pain Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Cancer Pain Therapeutics: by End User USD Million (2018-2023)
  • Figure 7. South America Cancer Pain Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Cancer Pain Therapeutics Share (%), by Country
  • Figure 9. Europe Cancer Pain Therapeutics Share (%), by Country
  • Figure 10. MEA Cancer Pain Therapeutics Share (%), by Country
  • Figure 11. North America Cancer Pain Therapeutics Share (%), by Country
  • Figure 12. Global Cancer Pain Therapeutics: by Type K Tons (2018-2023)
  • Figure 13. Global Cancer Pain Therapeutics: by Application K Tons (2018-2023)
  • Figure 14. Global Cancer Pain Therapeutics: by End User K Tons (2018-2023)
  • Figure 15. South America Cancer Pain Therapeutics Share (%), by Country
  • Figure 16. Asia Pacific Cancer Pain Therapeutics Share (%), by Country
  • Figure 17. Europe Cancer Pain Therapeutics Share (%), by Country
  • Figure 18. MEA Cancer Pain Therapeutics Share (%), by Country
  • Figure 19. North America Cancer Pain Therapeutics Share (%), by Country
  • Figure 20. Global Cancer Pain Therapeutics: by Type USD/Units (2018-2023)
  • Figure 21. Global Cancer Pain Therapeutics share by Players 2023 (%)
  • Figure 22. Global Cancer Pain Therapeutics share by Players (Top 3) 2023(%)
  • Figure 23. Global Cancer Pain Therapeutics share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. BioDelivery Science (United States) Revenue, Net Income and Gross profit
  • Figure 26. BioDelivery Science (United States) Revenue: by Geography 2023
  • Figure 27. ProStrakan Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. ProStrakan Group (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 31. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Daiichi Sankyo (Japan) Revenue: by Geography 2023
  • Figure 33. Eli-lilly (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli-lilly (United States) Revenue: by Geography 2023
  • Figure 35. Galena Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 36. Galena Biopharma (United States) Revenue: by Geography 2023
  • Figure 37. Grunenthal Group (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Grunenthal Group (Germany) Revenue: by Geography 2023
  • Figure 39. GW Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GW Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Hospira (United States) Revenue, Net Income and Gross profit
  • Figure 42. Hospira (United States) Revenue: by Geography 2023
  • Figure 43. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 44. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 45. Global Cancer Pain Therapeutics: by Type USD Million (2024-2029)
  • Figure 46. Global Cancer Pain Therapeutics: by Application USD Million (2024-2029)
  • Figure 47. Global Cancer Pain Therapeutics: by End User USD Million (2024-2029)
  • Figure 48. South America Cancer Pain Therapeutics Share (%), by Country
  • Figure 49. Asia Pacific Cancer Pain Therapeutics Share (%), by Country
  • Figure 50. Europe Cancer Pain Therapeutics Share (%), by Country
  • Figure 51. MEA Cancer Pain Therapeutics Share (%), by Country
  • Figure 52. North America Cancer Pain Therapeutics Share (%), by Country
  • Figure 53. Global Cancer Pain Therapeutics: by Type K Tons (2024-2029)
  • Figure 54. Global Cancer Pain Therapeutics: by Application K Tons (2024-2029)
  • Figure 55. Global Cancer Pain Therapeutics: by End User K Tons (2024-2029)
  • Figure 56. South America Cancer Pain Therapeutics Share (%), by Country
  • Figure 57. Asia Pacific Cancer Pain Therapeutics Share (%), by Country
  • Figure 58. Europe Cancer Pain Therapeutics Share (%), by Country
  • Figure 59. MEA Cancer Pain Therapeutics Share (%), by Country
  • Figure 60. North America Cancer Pain Therapeutics Share (%), by Country
  • Figure 61. Global Cancer Pain Therapeutics: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • BioDelivery Science (United States)
  • ProStrakan Group (United Kingdom)
  • Teva Pharmaceuticals (Israel)
  • Daiichi Sankyo (Japan)
  • Eli-lilly (United States)
  • Galena Biopharma (United States)
  • Grunenthal Group (Germany)
  • GW Pharmaceuticals (United Kingdom)
  • Hospira (United States)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Meda Pharmaceuticals (United Kingdom) , Orexo (Sweden) , Sanofi (France) , Sorrento Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 211 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Pain Therapeutics Market Quantitative research analysis
Global Cancer Pain Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as BioDelivery Science (United States), ProStrakan Group (United Kingdom), Teva Pharmaceuticals (Israel), Daiichi Sankyo (Japan), Eli-lilly (United States), Galena Biopharma (United States), Grunenthal Group (Germany), GW Pharmaceuticals (United Kingdom), Hospira (United States) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase Awareness about Cancer Pain Therapy " is seen as one of major influencing trends for Cancer Pain Therapeutics Market during projected period 2023-2029.
The Cancer Pain Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Cancer Pain Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Antinuclear Antibody Test Comprehensive Study by Type (Reagents and Assay Kits, Software and Services, Systems), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Scler...
$ 3750
Cell Culture Comprehensive Study by Type (Equipment, Consumables), Application (Biopharmaceutical, Cancer Research, Drug Screening & Development, Tissue Engineering & Regenerative Medicine, Others), ...
$ 3750
Coagulation Factors Comprehensive Study by Type (Coagulation Factor VIIa, Coagulation Factor IX, Coagulation Factor IX, Coagulation Factor IX, Coagulation Factor X, Others), Application (Pharmacy, Ho...
$ 3450
Engineered T Cells Comprehensive Study by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor (TCR), Chimeric Antigen Receptor (CAR)), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Me...
$ 3450
Chronic Obstructive Pulmonary Disorder Comprehensive Study by Type (Chronic Bronchitis, Emphysema), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Medication Type (Bronchodi...
$ 3750
Camellia Oil Comprehensive Study by Type (Extra Virgin camellia Oil, Pure camellia Oil, Pomace camellia Oil), Application (Food, Cosmetics, Pharmaceuticals, Chemical Industry), Distribution Channel (...
$ 3500